ClinicalTrials.gg

Program

Fusidic Acid

Also written as “CEM-102”, “sodium fusidate” and “Fusidic Acid 1%”.

Its studies are mostly in Conjunctivitis, Bacterial · Impetigo · Cystic Fibrosis · Osteomyelitis · Cellulitis, led by 4 companies.

Furthest: phase 4, since Oct 5, 20158 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrevus50 open or runningphase 3since Oct 5, 2015Jul 28, 2009none ahead
Aceragen10 open or runningphase 2since Nov 29, 2022Nov 29, 2022none ahead
Baxis Pharmaceuticals11 open or runningphase 3since Mar 19, 2025Mar 19, 2025none ahead
LEO Pharma10 open or runningphase 4since Sep 29, 2009Sep 29, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2009First study: phase 2 study in Skin Diseases, BacterialNew to ArrevusArrevus · NCT00948142 · 198 enrolled · United States
  2. Sep 29, 2009LEO Pharma's first study: phase 4 study in ImpetigoNew to LEO PharmaLEO Pharma · NCT00986856 · 58 enrolled · Norway, Sweden
  3. Dec 18, 2012Phase 2 study in Prosthetic Joint Infections of HipArrevus · NCT01756924 · 14 enrolled · United States
  4. Oct 5, 20152 phase 3 studiesArrevus · NCT02570490, NCT02569541
  5. Sep 23, 2021Phase 2 study in MelioidosisArrevus · NCT05105035 · 125 enrolled · Thailand
  6. Nov 29, 2022Aceragen's first study: phase 2 study in Cystic FibrosisNew to AceragenAceragen · NCT05641298 · United States
  7. Mar 19, 2025Baxis Pharmaceuticals's first study: phase 3 study in Conjunctivitis, BacterialNew to Baxis PharmaceuticalsBaxis Pharmaceuticals · NCT06911424 · 400 planned · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Elongation factor G inhibitor; Elongation factor G inhibitor”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06911424Conjunctivitis, Bacterial · United States3RecruitingBaxis PharmaceuticalsMar 16, 2026400
NCT05641298Cystic Fibrosis · United States2WithdrawnAceragenSep 20230
NCT05105035Melioidosis · Thailand2CompletedArrevusOct 10, 2023125
NCT02570490Cellulitis · United States, Puerto Rico3CompletedArrevusNov 2016716
NCT02569541Osteomyelitis · United States3CompletedArrevusOct 17, 201730
NCT01756924Prosthetic Joint Infections of Hip · United States2TerminatedArrevusJul 201414
NCT00986856Impetigo · Norway, Sweden4TerminatedLEO PharmaMar 200558
NCT00948142Skin Diseases, Bacterial · United States2CompletedArrevusMar 2010198

How it is read

Names in the registry

  • “CEM-102”, 3 entries
  • “sodium fusidate”, 2 entries
  • “Fusidic Acid 1%”, 1 entry
  • “Fucidin® cream”, 1 entry
  • “ARV-1801”, 1 entry

Codes read as this program: ARV1801.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Fusidic Acid (Arrevus): development program | ClinicalTrials.gg